mrx-2843
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 22, 2018 (NCT03510104)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
MERTK inhibitor
FLT3 inhibitor
Chemistry & pharmacology
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650408 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04872478 | Phase 1 | Oct 30, 2021 | Emory University, Meryx, University of North Carolina at Chapel Hill |
| NCT04762199 | Phase 1 | Feb 24, 2021 | Emory University, National Cancer Institute (NCI) |
| NCT03510104 | Phase 1 | May 22, 2018 | Emory University, Meryx |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emory University | Academic/Hospital | 3 | 1 | 1 | 2018 |
| Meryx | For profit | 2 | 2 | 1 | 2018 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2021 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1